Skip to main
  1. Stocks
  2. Progyny
  3. Forecast
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is supported by a differentiated fertility and family-building platform that is winning share, as shown by the record 1.3M new covered lives, near-100% retention, and more than 85 new clients expected to onboard, including large marquee accounts. Its Q3 performance reinforced the thesis that demand remains strong and execution is improving, with revenue of $341.3M, EBITDA of $58.4M, gross margin expansion to 24.5%, and operating cash flow of $57M showing both scale and cash generation. The outlook is further strengthened by an under-penetrated $10B U.S. fertility insurance market, expanding cross-sell opportunities across more than 3M lives, and a balance sheet that supports ongoing share repurchases and disciplined growth.

Bears say

Progyny is facing a tougher fundamental backdrop as elevated attrition, utilization pressure, and an economic downturn could reduce member counts and slow employer adoption of fertility benefits. Its utilization-driven model has already shown quarter-to-quarter volatility, while slower new solution revenue, employment sensitivity, and uncertainty around reproductive rights could further weaken demand and visibility. Competition from traditional carriers and well-funded carve-out rivals, plus pharmacy and physician-network bottlenecks, raises execution risk and supports a more conservative valuation framework tied to moderation in growth.

Progyny (PGNY) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 11 analysts, Progyny (PGNY) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PGNY stock data and trends